Eli Lilly (LLY +2%) moves up today after its Q4 beat across the board. Total revenue and net sales both declined Y/Y however, as Zyprexa's patent expiration weighed on results. Sales of the drug declined by 49%, but were offset somewhat by a surge in sales of Cymbalta, which jumped by jumped 20% to $1.42B and animal-health sales, which rose 18% to $554.1M. For FY13, Lilly expects to earn between $4.10 to $4.25 per share on sales of $22.6B to $23.4B. Street estimates are for $3.83 on revenue of $22.93B.